市场调查报告书
商品编码
1492568
固定剂量设备市场:按设备类型、适应症、分销管道和最终用户划分 - 2024-2030 年全球预测Fixed Dose Device Market by Device Type (Inhalers, Injectors, Nasal Sprays), Indication (Cardiovascular Diseases, Diabetes, Respiratory Disorders), Distribution Channel, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年固定剂量设备市场规模为91.7亿美元,预计2024年将达到100.3亿美元,2030年将达到176.3亿美元,复合年增长率为9.78%。
定量装置是指医疗实务中常用的工具或机制,旨在提供特定的预定剂量的药物,透过确保您收到正确剂量的药物,为患者提供治疗所需的准确剂量。过量的风险。这些设备广泛用于糖尿病等慢性病的治疗。它可以让您维持恆定剂量的胰岛素,这对于稳定血糖值至关重要。在公共卫生领域同样重要的是,简化大规模免疫接种并确保集体爆发期间准确的药物输送可以最大限度地提高免疫规划和公共卫生干预措施的有效性。随着心血管疾病和糖尿病等慢性疾病的盛行率增加,需要一致的药物管理,并且可以提高这些新治疗方法有效性的计量装置的使用正在增加。此外,对药物研究的投资正在推动新药的开发,并辅以创新的输送系统。然而,获得计量设备的核准通常需要大量时间和资源,阻碍了市场成长。此外,先进的设备设计和技术(例如数位追踪和提醒)可能会得到开发,并有望增加世界各地最终用户的设备使用量。
主要市场统计 | |
---|---|
基准年[2023] | 91.7亿美元 |
预测年份 [2024] | 100.3亿美元 |
预测年份 [2030] | 176.3亿美元 |
复合年增长率(%) | 9.78% |
区域洞察
在美洲,尤其是美国和加拿大,由于FDA的严格监管,计量器械产业呈现稳健的成长动能。这是为了促进创新并确保药物传递的精确性,这对于糖尿病和心血管疾病等常见慢性病的管理至关重要。该地区心血管疾病和糖尿病的盛行率不断上升,需要准确、方便的剂量解决方案,从而推动了对计量设备的需求。新兴国家医疗保健服务的改善和製药行业的成长推动了美洲和亚太地区市场的快速扩张。中国和印度等国家的中等收入阶层不断增加,本地製造和研发活动不断增加,对先进医疗设备的需求也不断增加。欧洲、中东和非洲计量设备市场的特点是医疗保健支出高、监管标准严格。德国和挪威等国家正在迅速增加对医疗保健领域的投资,这推动了欧洲地区的市场成长。儘管中东和非洲地区仍处于发展过程中,但随着各国政府加强加强该地区的医疗保健体系,该地区已显示出快速成长的迹象。
FPNV定位矩阵
FPNV 定位矩阵对于评估固定剂量设备市场供应商的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对固定剂量设备市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对固定剂量设备市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[185 Pages Report] The Fixed Dose Device Market size was estimated at USD 9.17 billion in 2023 and expected to reach USD 10.03 billion in 2024, at a CAGR 9.78% to reach USD 17.63 billion by 2030.
A fixed-dose device refers to a tool or mechanism designed to deliver a specific, predetermined dose of medication commonly used in medical settings, which ensures that patients receive the exact dose of medication for their treatment with each use, which minimizes the risk of underdosing or overdosing. These devices are widely utilized in managing chronic diseases such as diabetes. They administer consistent insulin doses, which are vital for stabilizing blood glucose levels. They are equally important in public health, streamlining mass vaccination efforts and ensuring accurate drug delivery during outbreaks, thereby maximizing the effectiveness of immunization programs and public health interventions. The growing prevalence of chronic diseases such as cardiovascular conditions and diabetes necessitates consistent medication management and thus contributes to the increased use of fixed-dose devices, which can improve the effectiveness of these new therapies. Additionally, investments in pharmaceutical research are propelling the development of new drugs complemented by innovative delivery systems. However, receiving approvals for fixed-dose devices is often lengthy and resource-intensive, hindering market growth. Moreover, the potential development of advanced device design and technology, such as digital tracking and reminders, are expected to encourage device utility by end users worldwide.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 9.17 billion |
Estimated Year [2024] | USD 10.03 billion |
Forecast Year [2030] | USD 17.63 billion |
CAGR (%) | 9.78% |
Regional Insights
In the Americas, specifically in the United States and Canada, the fixed-dose device industry is showing robust growth due to stringent FDA oversight, which encourages innovation and ensures drug delivery accuracy, which is crucial for managing prevalent chronic conditions like diabetes and cardiovascular diseases. The growing prevalence of cardiovascular diseases and diabetes within the region necessitates precise and convenient dosing solutions, driving demand for fixed-dose devices. The Americas and the Asia Pacific rapid market expansion is fueled by increasing healthcare access and pharmaceutical sector growth in emerging economies. The rising middle-class demographic in countries such as China and India and growing local manufacturing and R&D activities amplify the demand for advanced medical devices. The fixed-dose device market in EMEA is characterized by high healthcare spending and stringent regulatory standards. Countries such as Germany and Norway are rapidly increasing their investments in the healthcare sector, which is driving the growth of the European region's market. The Middle East and Africa, though at a nascent stage, are showing signs of rapid growth with growing government initiatives for strengthening the healthcare system within the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Fixed Dose Device Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Fixed Dose Device Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Fixed Dose Device Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Indian Pharmaceutical Firms Target Global Weight-Loss Drug Market with Generic Versions of Wegovy
Cadila Healthcare, USV Pvt. Ltd., and Emcure are at various stages of research and development to replicate generic alternatives to Novo Nordisk's popular drug, Wegovy. This strategic move is driven by the growing global demand for effective weight-loss treatments amidst rising obesity rates. These firms aim to provide more accessible and affordable options while ensuring compliance with international quality standards to capture a share of this lucrative market. [Published On: 2024-02-23]
EU Regulatory Review of Lilly's Mounjaro Multi-Dose Pen for Diabetes Treatment
The European Medicines Agency (EMA) initiated a review of Eli Lilly and Company's Mounjaro (tirzepatide) for its use in a multi-dose pen format. Mounjaro, known for its effectiveness in managing blood sugar levels, has been proposed as a pen device designed to administer fixed doses, enhancing patients' ease of use. This step supports potential regulatory approval in the European market and emphasizes ongoing efforts to innovate diabetes management solutions. The multi-dose pen aims to offer a convenient option for diabetes patients, aligning with modern healthcare needs and patient compliance strategies. [Published On: 2024-02-19]
Novo Nordisk Expands Portfolio with USD 154 Million Acquisition of Biocorp
Novo Nordisk successfully completed the acquisition of Biocorp for USD 154 million. This acquisition is pivotal as it adds Biocorp's innovative Mallya device, a Bluetooth-enabled clip-on device enhancing traditional insulin pens, to Novo Nordisk's portfolio. This merger signifies Novo Nordisk's commitment to integrating digital solutions into its diabetes care provisions, aiming to improve overall treatment outcomes through advanced technology. [Published On: 2023-06-06]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Fixed Dose Device Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Fixed Dose Device Market, highlighting leading vendors and their innovative profiles. These include Becton, Dickinson and Company, CeQur Corporation, Eli Lilly and Company, Gerresheimer AG, Insulet Corporation, Medtronic plc, Nemera Development S.A., Novo Holdings A/S, Owen Mumford Limited, Phillips-Medisize by Koch Industries, Inc., Sanofi Winthrop Industrie, SHL Medical AG., Solteam Incorporation Co., Ltd., SOOIL Developments Co., Ltd, Tandem Diabetes Care, Inc., Tata Elxsi Limited by Tata Group, West Pharmaceutical Services, Inc., Wilhelm Haselmeier GmbH & Co, and Ypsomed Holding AG.
Market Segmentation & Coverage